Reports Q3 revenue $46.28M, consensus $41.96M. “Heartflow (HTFL) delivered an outstanding third quarter of 2025,” said John Farquhar, President and CEO of Heartflow. “Durable growth in our FFRCT business and rapid expansion of our installed base drove third quarter total revenue up 41% year-over-year. Physician interest continues to build in Heartflow Plaque Analysis, which increases our confidence in this second wave of growth following broad commercial payor coverage. With continued business momentum and a strengthened balance sheet following our IPO, we believe we are well-positioned to expand our market leadership.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTFL:
- Heartflow announces data from FISH&CHIPS Study on Heartflow Plaque Analysis
- HeartFlow’s Innovative Study on Cardiac Risk in NFL Alumni: A Potential Game-Changer
- HeartFlow’s COMPLETE Study: A New Frontier in Coronary Artery Disease Evaluation
- Heartflow introduces Heartflow PCI Navigator
- Heartflow announces FDA clearance of plaque analysis algorithm, Cigna coverage